Tirzepatide vs Retatrutide: Research Comparison
A Side-By-Side Research Comparison Of Tirzepatide And Retatrutide - dual versus triple incretin receptor agonists in weight-research models. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Tirzepatide | Retatrutide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | Dual GIP/GLP-1 receptor co-agonist (twincretin); synthetic 39-residue peptide with C18 fatty diacid for albumin binding | Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor |
| Evidence Tier | Approved Drug | Investigational |
| Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect |
| Molecular Weight | 4813.45 Da | 4731.3 Da |
| Amino Acid Sequence | 39-aa acylated peptide (C20 diacid) | 39-aa GIP/GLP-1/glucagon tri-agonist (acylated) |
| CAS Number | 2023788-19-2 | 2381089-83-2 |
| Half-Life | ~1 week | ~1 week |
| Studied For | Type 2 diabetes management, Chronic weight management / obesity, Obstructive sleep apnea in obesity (FDA approved 2024), Non-alcoholic fatty liver disease (NAFLD/MASH) | Obesity / overweight, Type 2 diabetes, Liver fat / MASLD / NAFLD, Triple agonist weight loss |
About Tirzepatide
The approved dual-incretin weight-loss and diabetes drug; compounded versions are not FDA-evaluated.
Read The Full Tirzepatide MonographAbout Retatrutide
An investigational triple-agonist weight-loss peptide with strong early trial results.
Read The Full Retatrutide MonographKey Differences
- Evidence tier differs: Tirzepatide is classified as Approved Drug; Retatrutide is classified as Investigational.
- Primary molecular target differs: Tirzepatide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression; Retatrutide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.